RenovoDerm
RenovoDerm is a private Ohio-based medical device company that develops and commercializes fully synthetic, bioabsorbable 3D electrospun wound matrices — led by the FDA-cleared Phoenix Wound Matrix — for acute, chronic, and burn wounds in commercial hospitals and federal VA/DoD healthcare facilities.
- Company typePrivate
- Founded2016
- HeadquartersColumbus, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What RenovoDerm does
RenovoDerm, LLC is a privately held regenerative medicine company founded in 2016 and headquartered in Dublin, Ohio, that develops and commercializes synthetic wound care devices for the treatment of acute, chronic, and burn wounds. The company's flagship product, Phoenix Wound Matrix, is a 3D electrospun synthetic polymer matrix engineered to mimic native extracellular matrix (ECM) morphology. Unlike allogeneic or xenogeneic skin substitutes, the product is fully synthetic, contains no human or animal tissue, and biodegrades into alpha-hydroxy acids and fatty acids that lower local pH and provide lactate-mediated effects to address wound chronicity and persistent inflammation. The technology platform originates from technical parent Nanofiber Solutions (10+ years of electrospun scaffold development), and RenovoDerm itself operates as a commercial subsidiary under Paragen Technologies, LLC.
The commercial portfolio includes Phoenix Wound Matrix (the primary FDA 510(k)-cleared product), Anthem Wound Matrix (a private-label variant for government channels), and the Rotium Bioresorbable Wick for orthopedic tendon-to-bone repair. Revenue is generated through unit-based sales of the device to healthcare providers, reimbursed under dedicated HCPCS code C1849 as a high-cost skin substitute under the Medicare Outpatient Prospective Payment System. Go-to-market is hybrid: enterprise field sales through independent sales representatives and distributors targeting surgical specialties (Podiatry, Vascular, General, Plastics, Orthopedics, Dermatology) at commercial hospitals, alongside government-channel distribution via Academy Medical's DoD DAPA contract and Regenisource's SDVOSB IDIQ contract for VA and military facilities. As of May 2026, RenovoDerm announced a merger with Atreon Orthopedics to combine synthetic biomaterials platforms across multiple surgical specialties.
RenovoDerm firmographics
Firmographics- Name
- RenovoDerm
- Legal name
- RenovoDerm LLC
- Website
- https://renovoderm.tech
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RenovoDerm is a private Ohio-based medical device company that develops and commercializes fully synthetic, bioabsorbable 3D electrospun wound matrices — led by the FDA-cleared Phoenix Wound Matrix — for acute, chronic, and burn wounds in commercial hospitals and federal VA/DoD healthcare facilities.
- Ownership category
- akta.pro rank
RenovoDerm industry classification
Industry- Product category
- Advanced Wound Care Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)
- akta.pro secondary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where RenovoDerm is headquartered
LocationHeadquarters
- HQ city
- Columbus
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
RenovoDerm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Phoenix Wound Matrix Sales: Sale of FDA-cleared synthetic wound care devices to healthcare providers and institutions. Product is reimbursed under HCPCS code C1849 as a high-cost skin substitute under Medicare Outpatient Prospective Payment System.
- Anthem Wound Matrix Sales: Private label brand of Phoenix Wound Matrix distributed through Regenisource to government healthcare facilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Quote-based pricing for healthcare institutions |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
RenovoDerm product offering
Product offeringCore offering
RenovoDerm develops, manufactures, and sells advanced wound care products built on proprietary 3D electrospun synthetic polymer matrix technology designed to mimic native extracellular matrix morphology. Its flagship Phoenix Wound Matrix is an FDA 510(k)-cleared, fully synthetic, fully bioabsorbable device for the treatment of acute, chronic, and burn wounds, reimbursed under Medicare HCPCS code C1849 and sold to hospitals, surgeons, and federal (VA/DoD) healthcare facilities.
Product overview
RenovoDerm offers a focused portfolio of advanced wound care products centered on its core Phoenix Wound Matrix technology. The flagship Phoenix Wound Matrix is a 3D electrospun synthetic polymer matrix that provides a temporary microenvironment supporting endogenous wound healing. Anthem Wound Matrix is a private-label version of the same core technology distributed through government channels. The company also offers the Rotium Bioresorbable Wick for orthopedic applications. All products leverage electrospun polymer technology designed to mimic the extracellular matrix (ECM) and promote tissue regeneration rather than protracted inflammation.
Differentiator
Problem solved
Functional benefit
Brands
- Phoenix Wound Matrix: Primary product - a 3D electrospun synthetic polymer matrix for wound healing, designed to mimic extracellular matrix for tissue regeneration of acute and chronic wounds, and burns
- ANTHEM Wound Matrix
Products and services
- Phoenix Wound Matrix A 3D electrospun synthetic polymer matrix wound care device designed to improve wound healing outcomes by addressing chronicity and persistent inflammation. Fully resorbable, fully synthetic, and contains no human or animal tissue/cells, providing a temporary microenvironment that supports endogenous wound healing and regeneration of native tissue. FDA 510(k) cleared for acute, chronic, and burn wounds; reimbursed under Medicare HCPCS code C1849.
- ANTHEM Wound Matrix
Quantifiable outcome
- By day 31, wounds were completely re-epithelialized with mature granulation tissue and receding inflammatory response in GLP animal study
- +2 more outcomes
Companies that use RenovoDerm
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
RenovoDerm technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RenovoDerm partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Atreon OrthopedicscoreMerger announcement combining RenovoDerm and Atreon Orthopedics synthetic biomaterials platforms for tissue repair. The merger aims to expand applications and clinical evidence, supporting scalable growth across multiple surgical specialties. Post-merger, RenovoDerm operates as part of the combined entity.
- Nanofiber SolutionscoreTechnical parent company with 10+ years experience in electrospun scaffold technology. Developed the platform technology that created Phoenix Wound Matrix. Nanofiber Solutions designs and manufactures 3D nanofiber scaffolds designed to mimic the extracellular matrix found within the body.
- Paragen TechnologiescoreParent company of a family of companies focused on diverse clinical areas including wound care, orthopedics, peripheral vascular, and hernia repair. Ronald Bracken serves as CEO of both Paragen Technologies and its commercial subsidiaries including RenovoDerm.
- Ikove Capital (iKove)minorStartup nursery partner that believes in unlocking the potential of technology commercialization, bringing disruptive technology to market.
- Academy MedicalcoreGovernment contractor providing access to DoD DAPA contract for Phoenix Wound Matrix and Rotium Bioresorbable Wick products. Academy Medical enables access to federal government medical facilities and helps companies navigate government contracting processes.
- RegenisourcecoreSDVOSB (Service-Disabled Veteran-Owned Small Business) providing IDIQ contract access for ANTHEM Wound Matrix distribution to help heal veteran and military wounds. Customer service available at 877-862-5478.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
RenovoDerm competitors and assessment
Company assessmentDirect peers
- MiMedx Group: Direct competitor in skin substitutes and advanced wound care; RenovoDerm's CCO Hilary Dixon previously held senior marketing roles at MiMedx, and both companies compete in the same C1849-reimbursed synthetic/biologic skin substitute category.
- Organogenesis: Direct competitor in skin substitutes and wound healing (e.g., Apligraf, Dermagraft), serving similar chronic wound patient populations and selling through overlapping hospital, VA, and outpatient channels.
- Atreon Orthopedics: Synthetic biomaterials company in rotator cuff and tendon repair (Rotium); merged with RenovoDerm in 2026 and now shares the same corporate parent (Paragen Technologies), making it the most directly comparable peer for the combined tissue-repair platform.
Emerging players
- PolarityTE: Smaller regenerative medicine company developing autologous skin and soft-tissue products; overlaps with RenovoDerm in skin regeneration and wound healing, though with a different (cellular) technology approach.
- Celularity: Cellular therapy and regenerative medicine company with wound care applications (e.g., Biovance); competes in the same advanced skin substitute space with a placental-tissue-based approach vs. RenovoDerm's fully synthetic matrix.
Broad incumbents
- Coloplast: Established wound and skin care incumbent with a portfolio of advanced dressings; competes with Phoenix in chronic wound management for diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
- ConvaTec: Major wound and ostomy care player (e.g., AQUACEL, InnovaMatrix) with overlapping hospital and government channel presence; competes directly with Phoenix in advanced skin substitute dressings.
- Mölnlycke Health Care: Global wound care and surgical solutions provider (e.g., Mepilex, Mepitel); competes with Phoenix in hospital-based advanced wound care across the same surgical specialties RenovoDerm targets.
- Integra LifeSciences: Broad medical device incumbent with a sizable regenerative tissue/wound care portfolio (e.g., Integra Dermal Regeneration Template) and orthopedic/soft-tissue lines; competes with Phoenix in advanced wound care and with the post-merger Atreon/RenovoDerm platform in tissue repair.
- Smith+Nephew: Global incumbent in advanced wound management (e.g., PICO, ALLEVYN, OASIS) and orthopedics; competes with Phoenix in hospital wound care and with RenovoDerm's combined tissue-repair platform in surgical applications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
RenovoDerm social profiles
Digital presenceRenovoDerm financial estimates
Financial estimateRevenue estimate
Valuation estimate
RenovoDerm leadership team
Management profileNumber of profiles
Profiles3 records
RenovoDerm funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RenovoDerm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RenovoDerm
What does RenovoDerm do?
RenovoDerm develops, manufactures, and sells advanced wound care products built on proprietary 3D electrospun synthetic polymer matrix technology designed to mimic native extracellular matrix morphology. Its flagship Phoenix Wound Matrix is an FDA 510(k)-cleared, fully synthetic, fully bioabsorbable device for the treatment of acute, chronic, and burn wounds, reimbursed under Medicare HCPCS code C1849 and sold to hospitals, surgeons, and federal (VA/DoD) healthcare facilities.
Is RenovoDerm a public or private company?
RenovoDerm is a private company. It is classified as corporate owned and is currently operating.
When was RenovoDerm founded?
RenovoDerm was founded in 2016. It employs 1 to 10 people.
Where is RenovoDerm based?
RenovoDerm is headquartered in Columbus, United States, in the North America region.
How does RenovoDerm make money?
Two revenue lines are on record. Phoenix Wound Matrix Sales are the primary driver. The others are anthem Wound Matrix Sales.
Who are RenovoDerm's main competitors?
Direct peers on record are MiMedx Group, Organogenesis and Atreon Orthopedics. Emerging players are PolarityTE and Celularity. Broad incumbents are Coloplast, ConvaTec, Mölnlycke Health Care, Integra LifeSciences and Smith+Nephew.
Does RenovoDerm have an API?
No public API is recorded for RenovoDerm.
What industry is RenovoDerm in?
RenovoDerm's product category is Advanced Wound Care Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3842.